Ibrutinib and novel BTK inhibitors in clinical development

Small molecule inhibitors targeting dysregulated pathways (RAS/RAF/MEK, PI3K/AKT/mTOR, JAK/STAT) have significantly improved clinical outcomes in cancer patients. Recently Bruton’s tyrosine kinase (BTK), a crucial terminal kinase enzyme in the B-cell antigen receptor (BCR) signaling pathway, has eme...

Full description

Saved in:
Bibliographic Details
Main Authors: Akinleye, Akintunde, Chen, Yamei, Mukhi, Nikhil, Song, Yongping, Liu, Delong
Format: Artigo
Language:Inglês
Published: BioMed Central 2013
Subjects:
Review
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC3751776/
https://ncbi.nlm.nih.gov/pubmed/23958373
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1756-8722-6-59
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items